Home
Explore Technologies
Stanford OTL
The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.
Contact
|
Explore Technologies
Diagnostic Markers And Targets In Human Heart Failure
Stanford Reference:
03-116
Abstract
The invention provides a method of treating or preventing heart failure or a disease or condition associated with heart failure comprising administering an effective dose of an apelin peptide or APJ receptor ligand to the subject. According to certain embodiments of the invention the apelin peptide is administered chronically. In certain embodiments of the invention the apelin peptide is administered in an amount effective to improve at least one hemodynamic parameter or prognostic variable for heart failure. Clinical conditions associated with heart failure include, but are not limited to, atherosclerosis, restenosis, ischemic cardiovascular diseases, idiopathic or viral cardiomyopathy, and the like.
Applications
Diagnosis, prognosis and treatment of heart failure:
New pharmacological targets
New markers for diagnosis of heart failure and recovery
Advantages
The role of these genes in human heart failure has not been previously described.
Innovators & Portfolio
Euan Ashley
more technologies from Euan Ashley »
Mary Chen
Thomas Quertermous
more technologies from Thomas Quertermous »
Patent Status
Published Application: 20050152836
Published Application: WO2005-1029066
Published Application: 20080182779
Issued : 7,947,280 (USA)
Date Released
5/28/2019 12:00
Licensing Contact
Imelda Oropeza, Senior Licensing Manager, Physcial Sciences
650-725-9039 (Business)
Request Info
97-059
Development of a Regulatable Retroviral-Vector System for Identification of Untranslated Regions of mRNAs
03-321
endothelial derived lipase (EDL) knockout mouse
06-327
Pbx1 knockout mice - (B6.129S-Pbx1tm3.1Mlc/J)
more technologies »
Related Keywords
cardiovascular
LS: molecular diagnostic: biomarker